Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.72 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.72 |
| ▸ | PTGES | O14684 | 2/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | DLAT | P10515 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | ACHE | P22303 | 14/20 | 0.59 |
| ▸ | MET | P08581 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14577497 | 0.88 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL12634392 | 0.88 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL21907266 | 0.88 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL98723 | 0.88 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL15694967 | 0.88 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL14233249 | 0.88 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| Methoxymethane SCHEMBL7942622 | 0.87 | SIRT2 (0.82) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL7624217 | 0.87 | SIRT2 (0.85) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL7871338 | 0.87 | SIRT2 (0.85) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL6135548 | 0.86 | SIRT2 (0.61) | SIRT2SIRT1PTGESSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101933917-A | Application of Hyperforin derivant in preparing drugs | UNIV ZHONGSHAN | 2011-01-05 | — | — | CN | disclosed |
| EP-1607099-A1 | Use of hyperforin derivatives as an antidepressant agent | INDENA S.p.A. (IT) | 2005-12-21 | — | — | EP | disclosed |
| EP-1086071-B1 | HYPERFORIN DERIVATIVES, THE USE THEREOF AND FORMULATIONS CONTAINING THEM | INDENA SPA (IT) | 2005-10-19 | — | — | EP | disclosed |
| US-6656510-B2 | Antidepressants | INDENA S.P.A. (IT) | 2003-12-02 | — | — | US | disclosed |
| WO-2000054785-A9 | STABILIZED BICYCLO[3.3.1]NONENES AND METHODS OF USE | SHAMAN PHARMACEUTICALS INC (US) | 2001-12-27 | — | — | WO | disclosed |
| US-20010020040-A1 | Hyperforin derivatives, use thereof and formulations containing them | INDENA S.P.A. (IT) | 2001-09-06 | — | — | US | disclosed |
| EP-1086071-A1 | HYPERFORIN DERIVATIVES, THE USE THEREOF AND FORMULATIONS CONTAINING THEM | INDENA S.p.A. (IT) | 2001-03-28 | — | — | EP | disclosed |
| WO-2000054785-A2 | STABILIZED BICYCLO[3.3.1]NONENES AND METHODS OF USE | SHAMAN PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000054760-A2 | BICYCLO (3.3.1) NONENES USEFUL FOR THE TREATMENT OF DIABETES AND HYPERTRIGLYCERIDEMIA | SHAMAN PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| WO-1999064388-A1 | HYPERFORIN DERIVATIVES, THE USE THEREOF AND FORMULATIONS CONTAINING THEM | INDENA S.P.A. (IT) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020040-A1 | Hyperforin derivatives, use thereof and formulations containing them | CRH, FOS, VIP | SIRT2 452/4885SIRT1 231/4885PTGES 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.